CAMBRIDGE, Mass., March 3, 2016 /PRNewswire/ -- TriNetX, a leader in international clinical research networks, announced today the signing of a collaboration agreement with Novartis to optimize clinical trial design and advance clinical research for Novartis programs.
Novartis researchers will gain access to clinical data in real time from TriNetX’s proprietary network of healthcare institutions representing over 30 million patients in the US and Europe to support clinical study and protocol design, site selection, and patient recruitment across a range of therapeutic areas and development stages.
Users of the TriNetX system can analyze patient populations with search criteria from demographic, diagnosis, procedure, medication, and laboratory test data, and TriNetX’s advanced analytics modules provide intelligence on which criteria have the most impact as well as the rate at which new patients present. Each data point in the TriNetX system can be traced to healthcare providers who have the ability to identify individual patients, allowing clinical researchers to develop virtual patient cohorts that can be recapitulated in real world clinical trial settings. Data in the TriNetX system is fully anonymized to the user.
“Our mission is to disrupt the clinical trial design space by unleashing the power of data that is currently locked away,” said Gadi Lachman, CEO, TriNetX. “Through our network, healthcare providers, pharma and contract research organizations can create strategic partnerships to improve clinical research and patient care, and we are honored to have Novartis as part of our network. We see this collaboration agreement as a win-win for Novartis, TriNetX, our member institutions, and ultimately patients.”
About TriNetX
TriNetX is a worldwide clinical data network of healthcare providers, pharmaceutical companies and contract research organizations used to enhance clinical trial design and accelerate patient recruitment. TriNetX enables researchers to find the right patients at the right sites for clinical trials. For more information, visit http://www.trinetx.com.
Contact
Bill Stetson
Marketing, TriNetX
+1 (857) 285-6038
bill.stetson@trinetx.com
Logo - http://photos.prnewswire.com/prnh/20160303/340354LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/trinetx-executes-agreement-to-revolutionize-clinical-trial-design-to-enhance-and-accelerate-the-development-of-new-drugs-300230793.html
SOURCE TriNetX, Inc.
